Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Efficacy and safety from the phase 2 CheckMate 436 study Meeting Abstract
| Authors: | Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta‐Shah, N. A.; Manley, T.; Francis, S.; Sharma, M.; Moskowitz, A. J. |
| Abstract Title: | Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: Efficacy and safety from the phase 2 CheckMate 436 study |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 157 |
| End Page: | 158 |
| Language: | English |
| ACCESSION: | 137029056 |
| DOI: | 10.1002/hon.114_2629 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Accession Number: 137029056 -- Entry Date: In Process -- Revision Date: 20190620 -- Publication Type: Article -- Supplement Title: Jun2019 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
